KP Tissue (KPT) AI Stock Analysis

• Market Cap: C$89.71M
• Dividend Yield: 8.06%
• Average Volume (3M): 18.39K
• Price to Earnings (P/E): 29.4
• Beta (1Y): 0.23
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: CA
• Employees: 2,700
• Sector: Consumer Defensive
• Sector Strength: 78
• Industry: Household & Personal Products
• EPS (TTM): 0.14
• Shares Outstanding: 10,000,916
• 10 Day Avg. Volume: 17,857
• 30 Day Avg. Volume: 18,388
• PEG Ratio: -0.56
• Price to Book (P/B): 1.22
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 24.19
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: C$9.33
• Price Target Upside: 4.01% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 3

• Rating: 59 Neutral
• Price Target: ―

KP Tissue's overall stock score reflects a mix of strengths and challenges. The strong balance sheet and positive earnings call outlook are significant positives, enhancing stability and growth potential. However, profitability issues, high P/E ratio, and mixed technical indicators present cautionary elements. The attractive dividend yield provides some valuation support, but overall, the stock's performance hinges on continued operational improvements and strategic execution amid external challenges.

KP Tissue Business Overview & Revenue Model

Company Description

KP Tissue Inc., through its interest in Kruger Products L.P., produces, distributes, markets, and sells a range of disposable tissue products in Canada and the United States. The company operates through two segments, Consumer and Away-From-Home. It offers bathroom and facial tissues, paper towels, and napkins, as well as manufactures private label tissue products. The company markets its products under the Cashmere, Purex, SpongeTowels, Scotties, White Swan, White Cloud, Chalet, Embassy, White Swan, and Metro brand names. The company sells its products to consumers through traditional retail channels, such as grocery stores, mass merchandisers, club and drug stores, convenience stores, and online retailers; and through distributors to businesses involved in commercial users in the property management, healthcare, food services, manufacturing, lodging industries, and public facilities. KP Tissue Inc. was incorporated in 2012 and is headquartered in Mississauga, Canada.

How the Company Makes Money

KP Tissue makes money through its equity interest in Kruger Products L.P., which generates revenue by manufacturing and distributing tissue products across North America. The company earns money by selling these products to major retailers, wholesalers, and commercial clients. Key revenue streams include sales from branded consumer products and private label offerings. Additionally, Kruger Products L.P. engages in strategic partnerships and has a robust distribution network that enhances its market reach, thereby contributing to its earnings.

KP Tissue Financial Statement Overview

Summary

KP Tissue's financial performance is mixed. The balance sheet is robust with no leverage, enhancing stability and scoring high. However, the income statement reveals profitability issues with historical losses, and cash flow analysis shows variability, indicating potential instability. The overall financial picture is cautiously optimistic but with significant challenges.

Income Statement

The income statement shows consistent challenges with profitability, as evidenced by negative EBIT in most periods. The company managed a positive net income in TTM (Trailing-Twelve-Months) but has faced historical losses. Revenue data is missing, making margin analysis impossible.

Balance Sheet

The balance sheet is strong with zero debt, reflected in a favorable debt-to-equity ratio. The equity ratio is high, indicating a stable financial structure. The company has maintained healthy stockholders' equity over the years.

Cash Flow

Cash flow analysis shows variability, with operating cash flow improving in TTM (Trailing-Twelve-Months). Free cash flow was positive in the latest period, but historical fluctuations suggest potential instability in cash management. The operating cash flow to net income ratio indicates some operational efficiency.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00
	Gross Profit
0.00	0.00	0.00	0.00	0.00
	EBIT
0.00	0.00	-12.55M	-321.00K	-634.00K
	EBITDA
619.00K	238.61M	752.00K	153.43M	197.84M
	Net Income Common Stockholders
2.43M	-4.94M	-10.25M	1.24M	-1.95M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
0.00	0.00	0.00	0.00	0.00
	Total Assets
71.31M	70.61M	81.71M	80.72M	71.31M
	Total Debt
0.00	0.00	0.00	0.00	0.00
	Net Debt
0.00	0.00	0.00	0.00	0.00
	Total Liabilities
1.80M	2.25M	7.68M	4.85M	4.99M
	Stockholders Equity
69.52M	68.36M	74.03M	75.87M	66.33M
Cash Flow		Free Cash Flow
0.00	6.98M	6.62M	1.15M	-2.44M
	Operating Cash Flow
0.00	6.98M	6.62M	1.15M	-2.44M
	Investing Cash Flow
6.97M	6.98M	6.62M	5.56M	5.59M
	Financing Cash Flow
-6.97M	-6.98M	-6.62M	-5.56M	-5.59M

KP Tissue Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 8.97
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:KPT, the sentiment is Positive. The current price of 8.97 is above the 20-day moving average (MA) of 8.67, above the 50-day MA of 8.23, and above the 200-day MA of 7.97, indicating a bullish trend. The MACD of 0.23 indicates Negative momentum. The RSI at 76.50 is Negative, neither overbought nor oversold. The STOCH value of 90.98 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:KPT.

KP Tissue Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EMP.A	79 Outperform	C$12.32B	18.81	12.64%	1.51%	1.05%	-6.94%
MRU	77 Outperform	C$23.67B	24.17	14.26%	1.32%	2.31%	4.45%
MFI	73 Outperform	C$3.39B	35.77	6.05%	3.30%	3.16%	―
RSI	72 Outperform	C$722.30M	11.59	14.43%	6.38%	11.35%	-4.31%
PBH	68 Neutral	C$3.65B	30.66	6.75%	4.18%	6.29%	24.34%
Sector *	65 Neutral	$8.91B	14.97	4.70%	203.30%	3.50%	-2.45%
KPT	59 Neutral	C$89.71M	29.36	4.37%	8.06%	―	―

KP Tissue Corporate Events

KP Tissue Declares Quarterly Dividend and Offers Reinvestment Plan

KP Tissue Inc. announced a quarterly dividend of $0.18 per common share, payable on April 15, 2025, to shareholders of record as of March 31, 2025. This dividend declaration aligns with a corresponding distribution by Kruger Products Inc., in which KPT holds a limited partnership interest. Additionally, KP Tissue offers a Dividend Reinvestment Plan (DRIP) for Canadian shareholders, allowing them to reinvest cash dividends into additional common shares. This announcement underscores KPT’s commitment to providing shareholder value and maintaining its strategic investment in Kruger Products, a key player in the North American tissue market.

KP Tissue Achieves Record Revenue in 2024 Amid Expansion Plans

KP Tissue Inc. reported record revenue exceeding $2 billion for 2024, with strong Adjusted EBITDA across all quarters, despite challenges like volatile pulp prices. The company is exploring the construction of a new manufacturing facility to enhance its market share and product offerings in North America. Additionally, KP Tissue is preparing contingency plans to address potential U.S. tariffs and is leveraging patriotic consumer sentiment in Canada through marketing campaigns.